Eric Benevich

CIK: 0001643653

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (20.0%)

Position reduction

Option Exercises (M)11 (36.7%)

Derivative conversions

Awards (A)7 (23.3%)

Compensation grants

Other (G, F, J, C, D, …)6 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NBIX

NEUROCRINE BIOSCIENCES INC

Officer

ATYR

aTYR PHARMA INC

Director

Discretionary Trading P&L

Holdings

Transaction History (30 total)

NBIX
NEUROCRINE BIOSCIENCES INC
Sep 11, 2026
Tax Payment(F)
Direct
3.4K shares at avg. $156.22$529K
NBIX
NEUROCRINE BIOSCIENCES INC
Sep 11, 2026
Award(A)
Direct
6.3K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Sep 9, 2026
Exercise(M)
Direct
3.2K shares at avg. $43.24$138K
NBIX
NEUROCRINE BIOSCIENCES INC
Sep 9, 2026
Sale(S)
Direct
2.2K shares at avg. $154.61$333K
ATYR
aTYR PHARMA INC
May 11, 2026
Award(A)
Stock Option (right to buy)
Direct
50K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
9K shares at avg. $124.12$1.1M
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Exercise(M)
Direct
2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $124.12$131K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Exercise(M)
Direct
2.1K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $124.12$140K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2026
Award(A)
Direct
16.6K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2026
Exercise(M)
Direct
2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $123.10$133K
NBIX
NEUROCRINE BIOSCIENCES INC
Jan 31, 2026
Exercise(M)
Direct
2.3K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Jan 31, 2026
Tax Payment(F)
Direct
1.3K shares at avg. $136.06$176K
NBIX
NEUROCRINE BIOSCIENCES INC
Nov 28, 2025
Exercise(M)
Direct
12.8K shares at avg. $35.99$462K
NBIX
NEUROCRINE BIOSCIENCES INC
Nov 28, 2025
Exercise(M)
Direct
6K shares at avg. $35.99$215K
NBIX
NEUROCRINE BIOSCIENCES INC
Nov 28, 2025
Sale(S)
Direct
6K shares at avg. $151.74$906K
ATYR
aTYR PHARMA INC
May 1, 2025
Award(A)
Stock Option (right to buy)
Direct
50K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Sale(S)
Direct
1.1K shares at avg. $116.71$123K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Exercise(M)
Direct
2.1K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Sale(S)
Direct
1.1K shares at avg. $116.74$128K
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 13, 2025
Exercise(M)
Direct
2K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2025
Award(A)
Stock Option
Direct
42.8K shares-
NBIX
NEUROCRINE BIOSCIENCES INC
Feb 12, 2025
Award(A)
Restricted Stock Unit
Direct
8K shares-

		Type	Shares	Price		Ownership
Sep 11, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	3,386	$156.22	$528,961	Direct
Sep 11, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Award(A)	6,275	-	$0	Direct
Sep 9, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	3,194	$43.24	$138,109	Direct
Sep 9, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	2,154	$154.61	$333,030	Direct
May 11, 2026	ATYR aTYR PHARMA INC	Award(A) Stock Option (right to buy)	50,000	-	-	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	8,963	$124.12	$1,112,488	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	1,961	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,058	$124.12	$131,319	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,083	-	$0	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,124	$124.12	$139,511	Direct
Feb 13, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Award(A)	16,613	-	$0	Direct
Feb 12, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,005	-	$0	Direct
Feb 12, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,082	$123.10	$133,194	Direct
Jan 31, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,294	-	$0	Direct
Jan 31, 2026	NBIX NEUROCRINE BIOSCIENCES INC	Tax Payment(F)	1,292	$136.06	$175,790	Direct
Nov 28, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	12,830	$35.99	$461,752	Direct
Nov 28, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	5,970	$35.99	$214,860	Direct
Nov 28, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	5,970	$151.74	$905,881	Direct
May 1, 2025	ATYR aTYR PHARMA INC	Award(A) Stock Option (right to buy)	50,000	-	-	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	1,056	$116.71	$123,245	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	2,083	-	-	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Sale(S)	1,098	$116.74	$128,183	Direct
Feb 13, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Exercise(M)	1,961	-	-	Direct
Feb 12, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Award(A) Stock Option	42,805	-	-	Direct
Feb 12, 2025	NBIX NEUROCRINE BIOSCIENCES INC	Award(A) Restricted Stock Unit	8,022	-	-	Direct

1-25 of 30 transactions

About BENEVICH ERIC

BENEVICH ERIC (SEC CIK 0001643653) files insider reports with the SEC as Chief Commercial Officer of NEUROCRINE BIOSCIENCES INC (NBIX) and Director of aTYR PHARMA INC (ATYR).

Signal8 holds 13 ownership filings by BENEVICH ERIC (1 Form 3, 12 Form 4), filed between Dec 12, 2024 and Sep 15, 2026. Those filings report 30 transactions, from Dec 10, 2024 to Sep 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BENEVICH ERIC's filings is in SAN DIEGO, CA.

Recent filings by BENEVICH ERIC

Sep 11, 2026: Tax withholding of NBIX shares (Form 4, code F).
Sep 11, 2026: Grant or award of NBIX shares (Form 4, code A).
Sep 9, 2026: Option exercise of NBIX shares (Form 4, code M).
Sep 9, 2026: Open-market sale of NBIX shares (Form 4, code S).
May 11, 2026: Grant or award of ATYR derivative securities (Form 4, code A).

Other insiders filing for NEUROCRINE BIOSCIENCES INC (NBIX)

MORROW GEORGE J, Director
Gano Kyle, Chief Executive Officer
ROBERTS EIRY, Chief Medical Officer
Onyia Jude, Chief Scientific Officer
Lippoldt Darin, Chief Legal Officer
Keswani Sanjay Chandru, Chief Medical Officer

How to read Form 4 transaction codes